Streptokinase: An Efficient Enzyme in Cardiac Medicine

Protein Pept Lett. 2020;27(2):111-119. doi: 10.2174/0929866526666191014150408.

Abstract

An imbalance in oxygen supply to cardiac tissues or formation of thrombus leads to deleterious results like pulmonary embolism, coronary heart disease and acute cardiac failure. The formation of thrombus requires clinical encounter with fibrinolytic agents including streptokinase, urokinase or tissue plasminogen activator. Irrespective to urokinase and tissue plasminogen activator, streptokinase is still a significant agent in treatment of cardiovascular diseases. Streptokinase, being so economical, has an important value in treating cardiac diseases in developing countries. This review paper will provide the maximum information to enlighten all the pros and cons of streptokinase up till now. It has been concluded that recent advances in structural/synthetic biology improved SK with enhanced half-life and least antigenicity. Such enzyme preparations would be the best thrombolytic agents.

Keywords: Streptococci; Streptokinase; drug; fibrinolytic agents; myocardial infarction; thrombolytic agent..

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / drug therapy*
  • Drug Stability
  • Half-Life
  • Humans
  • Protein Engineering / methods*
  • Recombinant Proteins / metabolism
  • Streptokinase / metabolism*
  • Streptokinase / pharmacokinetics
  • Streptokinase / therapeutic use
  • Synthetic Biology

Substances

  • Recombinant Proteins
  • Streptokinase